Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

This study found that DHT induces apoptosis in human keratinocyte cells via ERK activation, independently of androgen receptors and the Wnt/β-catenin pathway.

In this study, male-derived brain tissue exhibited higher cell death following ischemia compared to female-derived tissue, and certain steroid hormones showed different neuroprotective effects depending on the sex of the tissue.

This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.

In this study, increased corticosterone from chronic stress prolonged hair follicle stem cell quiescence in mice, inhibiting regeneration, but restoring Gas6 expression overcame this inhibition.

This study found that cepharanthine can inhibit gastric cancer cell activity by inducing oxidative stress and altering energy metabolism, suggesting its potential for gastric cancer treatment.

This study found that cephalanthine inhibited the growth of gastric cancer cells in vitro and in vivo by inducing oxidative stress and altering energy metabolism, suggesting its potential as a treatment for gastric cancer.

This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

This review highlights the pharmaceutical potential of secondary metabolites from Juniperus species, noting promising antitumor, antibacterial, and antiviral activities, but reports no new experimental findings.

This study reviews recent advancements in understanding caspases, highlighting their roles beyond apoptosis in cancer, inflammation, and neurological disorders, and discusses the potential and challenges of targeting caspases for therapeutic purposes.

In this study, researchers found that impaired cholesterol biosynthesis in hair follicles may trigger an inflammatory immune response linked to primary cicatricial alopecia, providing new insights into the disorder's pathogenesis.

This paper reviews the role of the telomere-telomerase system in cellular ageing and cancer, discussing potential therapies but reporting no new experimental results.

This review discusses nearly 70 patent applications for the treatment of androgenetic alopecia and other hair conditions, highlighting the mechanisms of action explored but reports no clinical results.

This study found that saw palmetto extract inhibits glioma cell proliferation and angiogenesis via the STAT3 pathway, suggesting its potential use as a complementary therapy for cancers with activated STAT3 signaling.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

This study isolated and characterized two distinct types of caspase-like proteases from human epidermis, suggesting their involvement in keratinocyte differentiation and apoptosis processes.

This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.

Caspase-3 helps control cell growth and organ size by activating YAP.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

This study found that the small molecule honokiol may protect against inflammation, collagen breakdown, and cell damage caused by cigarette smoke in skin cells cultured in vitro.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.

This review discusses androgen receptor targeting as a potential treatment strategy for triple-negative breast cancer and reports no new experimental outcomes.

This abstract provides a comprehensive overview of enzyme classification, function, and interaction with drugs, but does not present new research findings.

This study synthesized new heterocyclic steroid derivatives and reported their promising antiproliferative activity against breast and prostate cancer cell lines, highlighting selectivity and impact on signaling pathways even in cells resistant to certain treatments.

This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.

This review discusses how targeting protein degradation processes may help overcome cancer drug resistance, but reports no new clinical results and suggests further research for precise therapeutic strategies.